Publications
2023
Oral reovirus reshapes the gut microbiome and enhances antitumor immunity in colon cancer. (Under Revision)
Go EJ, Yang H, Lee SJ, Yang HG, Shin JA, Lee WS, Lim HS, Chon HJ, Kim C. PB101, a VEGF- and PlGF-targeting decoy protein, enhances antitumor immunity and suppresses tumor progression and metastasis. Oncoimmunology 2023 (IF 7.2)
Go EJ, Yang H, Park W, Lee WS, Kong SJ, Lee SJ, Han DK, Chon HJ, and Kim C. Systemic delivery of a STING agonist-loaded positively charged liposome selectively targets tumor immune microenvironment and suppresses tumor angiogenesis. Small 2023 (IF 15.153) 한빛사 선정 (Selected as Cover image)
Song YS, Yang H, Kang B, Cheon J, Kim I, Kim H, Lee WS, Sang YB, Jung S, Lim HY, Gaillard VE, Kim, C, and Chon HJ. Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma. Liver Cancer 2023 (IF 12.43) 한빛사 선정
Pal SK, Albiges L, Tomczak P, Suarez C, Voss MH, Velasco G, Chahoud J, Mochalova A, Procopio G, Mahammedi H, Zengerling F, Kim C, Osawa T, Angel M, Gupta S, Khan O, Bergthold G, Liu B, Kalaitzidou M, Huseni M, Scheffold C, Powles T, Choueiri TK. Atezolizumab plus cabozantinib versus cabozantinib for patients with renal cell carcinoma after progression with prior immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomized, open-label, phase 3 trial. The Lancet 2023 (IF 202.731).
Bae GH, Ryu YH, Han J, Kim SH, Park CG, Park JH, Kim DH, Chon HJ, Kim C, Choi SW, Park W.
Multifunctional porous microspheres encapsulating oncolytic bacterial spores and their potential for cancer immunotherapy. Biomater Sci. 2023 (IF 7.590)
Lee SH, Cheon J, Lee S, Kang B, Kim C, Shim HS, Park YN, Jung S, Choi SH, Choi HJ, Lee CK, Chon HJ. ARID1A mutation from targeted NGS predicts primary resistance to gemcitabine and cisplantin chemotherapy in advanced biliary tract cancer. Cancer Res Treat 2023 (IF 5.036)
Kim C, Yang H, Chon HJ. High Levels of Antidrug Antibodies Against Atezolizumab as a Predictive Marker for Clinical Outcomes in Patients With Hepatocellular Carcinoma—Reply. JAMA Oncol. 2023 (IF 33.006) 한빛사 선정
Kim Y, Yang H, Lee WS, Cheon J, Sang YB, Kang B, Chon HJ, Kim C. High levels of baseline serum IL-10 are associated with reduced clinical benefit from first-line immune checkpoint inhibitor therapy in advanced renal cell carcinoma. J Cancer 2023 (IF 4.478)
Cheon J, Kim H, Kim HS, Kim CG, Kim I, Kang B, Kim C, Jung S, Ha Y, Chon HJ. Atezolizumab plus bevacizumab in patients with Child-Pugh B advanced hepatocellular carcinoma. Ther Adv Med Oncol. 2023 (IF 5.485)
Yang H, Kang B, Ha Y, Lee SH, Kim I, Kim H, Lee WS, Kim G, Jung S, Rha SY, Gaillard VE, Cheon J, Kim C, and Chon HJ.
High serum IL-6 correlated with reduced clinical benefit of atezolizumab and bevacizumab in unresectable hepatocellular carcinoma. JHEP Reports 2023 (IF 9.9)
2022
Kim C*, Yang H*, Kim I, Kang B, Kim H, Kim H, Lee WS, Jung S, Lim HY, Cheon J, Chon HJ.
High levels of anti-drug antibodies against atezolizumab are associated with unfavorable clinical outcome and diminished T cell response in hepatocellular carcinoma. JAMA Oncol. 2022 (IF 33.006) 한빛사 선정
Sang YB, Yang H, Lee WS, Lee SJ, Kim SG, Cheon J, Kang B, Kim CW, Chon HJ, and Kim C.
High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma. Cancers 2022 (IF 6.575)
Ha Y, Kim JH, Cheon J, Jeon GS, Kim C#, Chon HJ#. Risk of variceal bleeding in patients with advanced hepatocellular carcinoma receiving ateolizumab/bevacizumab. Clin Gastroenterol Hepatol. 2022 (IF 13.576) 한빛사 선정
Lee WS*, Kim DS*, Kim JH*, Heo Y, Yang H, Go EJ, Kim JH, Lee SJ, Ahn BC, Yum JS, Chon HJ#, Kim C#.
Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust anti-tumor immune responses and enhances immune checkpoint blockade. Journal for Immunotherapy of Cancer 2022 (IF 13.751) 한빛사 선정
2021
Park HS*, Kim YM*, Kim S*, Lee WS, Kong SJ, Yang H, Kang B, Cheon JK, Shin SJ, Kim C#, Chon HJ#.
High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer.
Journal for Immunotherapy of Cancer 2021 (IF 13.751) 한빛사 선정Kim JH*, Lee WS*, Lee HJ, Yang H, Lee SJ, Kong SJ, Je S, Yang HJ, Jung J, Cheon JK, Kang B, Chon HJ#, Kim C#.
Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway.
Oncoimmunology 2021 (IF 8.110)Kim CW, Chon HJ#, Kim C#.
Combination immunotherapies to overcome intrinsic resistance to checkpoint blockade in microsatellite stable colorectal cancer. Cancers 2021 (IF 6.639)Ahn HJ, Chon HJ#, Kim C#.
Peripheral blood-based biomarkers for immune checkpoint inhibitors. International Journal of Molecular Sciences 2021 (IF 5.923)Cheon J, Lee CK, Sang YB, Choi HJ, Kim MH, Ji JH, Ko KH, Kwon CI, Kim DJ, Choi SH, Kim C, Kang B, Chon HJ.
Real-world efficacy and safety of nab-paclitaxel plus gemcitabine-cisplatin in patients with advanced biliary tract cancers: a multicenter retrospective analysis. Ther Adv Med Oncol 2021 (IF 8.168)Lee SJ*, Yang H*, Kim WR*, Lee YS, Lee WS, Kong SJ, Lee HJ, Kim JH, Kang BD, Chon HJ#, Kim C#.
STING activation normalizes the intraperitoneal vascular-immune microenvironment and suppresses peritoneal carcinomatosis of colon cancer. Journal for Immunotherapy of Cancer 2021 (IF 13.751) 한빛사 선정
2020
Go E-J*, Yang H*, Chon HJ*, Yang DS, Ryu WH, Kim DH, Han DK#, Kim C#, Park W#
Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. Cancers 2020 (IF 6.126)Lee YS*, Lee WS*, Kim CW*, Lee SJ, Yang H, Kong SJ, Ning J, Yang KM, Kang B, Kim WR, Chon HJ#, Kim C#.
Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with PD-1 blockade to suppress peritoneal carcinomatosis in colon cancer. Journal for ImmunoTherapy of Cancer 2020 (IF 10.252) 한빛사 선정Kim CG*, Kim C*, Yoon SE*, Kim KH, Choi SJ, Kang B, Kim HR, Park SH, Shin EC, Kim DJ, Chon HJ#, Chon HJ#, Lim HY#.
Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma. Journal of Hepatology 2020 (IF 20.582) 한빛사 선정
Oh C-M, Chon HJ#, Kim C#.
Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. International Journal of Molecular Sciences 2020 (IF 4.556)Lee WS*, Yang H*, Chon HJ# and Kim C#.
Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Experimental & Molecular Medicine 2020 한빛사 선정
Chon HJ and Kim C.
REACH-2: First biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma. Chinese Clinical Oncology 2020 (Editorial Commentary)
2019
Yang H, Lee WS, Kong SJ, Kim JH, Kim S, Kim G, Chon HJ#, Kim C#.
STING Activation Reprograms Tumor Vasculatures and Synergizes with VEGFR2 Blockade.
Journal of Clinical Investigation 2019 (Accepted, IF 12.282) (한국연구재단 선정 2019년 우수 기초연구성과 10개에 선정)
Kim H, Noh JH, Yang H, Lee WS, Kong SJ, Lee SJ, Lee YS, Kim WR, Kim JH, Chon HJ, Kim G#, Kim C#
STING signaling is a potential immunotherapeutic target in colorectal cancer. Journal of Cancer 2019 (Accepted, IF 3.182)
Chon HJ*, Lee WS*, Yang H, Kong SJ, Lee NK, Moon ES, Choi J, Han EC, Ahn JB, Kim JH, Kim C
Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade.
Clinical Cancer Research 2018 (E-pub, IF 10.199)
(Selected as Cover Image and Highlights of Issue) 미국암학회 (AACR) 2019 타이틀사진으로 선정)
Kim C*, Chon HJ*, Kim JH, Jung M, Nam JM, Kim HS, Kang B, Chung HC, Rha SY.
Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
European Journal of Cancer 2019, 112:20-28 (IF 7.191)
Chon HJ*, Kim C*, Cho A*, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY
The Clinical Implications of FDG-PET/CT Differ According to Histology in Advanced Gastric Cancer. Gastric Cancer 2018;22(1):113-122 (IF 5.454)
Kim C, Kim WR, Kim KY, Chon H, Beom SH, Kim H, Jung M, Shin SJ, Kim N, Ahn JB.
Predictive Nomogram for Recurrence of Stage I Colorectal Cancer Following Curative Resection. Clinical Colorectal Cancer 2018;17(3):513-518 (IF 4.507)
Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP.
A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer. BMC Cancer 2018, 18:332 (IF 3.288)
Kim C, Lee C, Chon HJ, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY.
PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer. Oncotarget 2017
Goh YH, Yoo J, Noh JH, Kim C. (Corresponding author)
Emerging Targeted Therapies in Advanced Bladder Cancer. Translational Cancer Research 2017.
Chon HJ, Hyung WJ, Kim C, Kim H, Park S, Park CH, Kim JH, Ahn JB, Chung HC, Rha SY, Noh SH, Jeung HC.
Differential Prognostic Implications of Gastric Signet Ring Cell Carcinoma: Stage Adjusted Analysis From a Single High-volume Center in Asia. Annals of Surgery 2017, 265(5):946-953 (IF 8.327)
Kim C, Yoo KH, Kim MH, Chon HJ, Lee SI, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, Rha SY, Lee SJ, Kim HS.
Different Subtypes of Epithelioid Sarcoma and Their Clinical Implication: Long-term Multi-Institutional Experience with a Rare Sarcoma. APMIS 2017, 125:223-229
Park JS, Kim IK, Han S, Park I, Kim C, Bae J, Oh SJ, Lee S, Kim JH, Woo DC, He Y, Augstin HG, Lee DH, Kim I, Koh GY.
Normalization of Tumor Vasculature by Tie2 Activation and Ang2 Inhibition Enhances Drug Delivery and Produces a Favorable Tumor Microenvironment. Cancer Cell 2016, 30:953-967 (IF 24.755)
Kim CG, Ahn JB, Jung M, Beom SH, Kim C, Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, Min BS, Kim H, Koom WS, Shin SJ.
Effects of microsatellite instability on recurrence patterns and outcomes in colorectal cancers. British Journal of Cancer 2016, 115(1):25-33
Kyu-Won Kim, Jae Kyung Roh, Hee-Jun Wee, Chan Kim.
Cancer Drug Discovery: Science and History. Springer; 1st ed. 2016. (ISBN-13: 978-9402408423)
Kim C, Kim EK, Jung H, Chon HJ, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SYm Kim SH, Kim HS.
Prognostic Implications of PD-L1 Expression in Patients with Soft Tissue Sarcoma. BMC Cancer 2016, 16:434
Kim C, Yang H, Park I, Chon HJ, Kim JH, Kwon WS, Lee WS, Kim TS, Rha SY.
Rho GTPase RhoJ is associated with gastric cancer progression and metastasis. J Cancer 2016, 7(11):1550-1556
Lim SM, Kim YN, Park KH, Kang BD, Chon HJ, Kim C, Kim JH, Rha SY.
Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients. BMC Cancer 2016, 16:385
Lim B*, Kim C*, Kim JH, Kwon WS, Lee WS, Kim JM, Park JY, Kim HS, Park KH, Kim TS, Park JL, Chung HC, Rha SY, Kim SY. (*Co-first author)
Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. Oncotarget 2016, 7(7):8055-66
Kim Y, Nam HJ, Lee J, Park DY, Kim C, Yu YS, Kim D, Park SW, Bhin J, Hwang D, Lee H, Koh GY, Baek SH.
Methylation-dependent Regulation of HIF-1α Stability Restricts Retinal and Tumour Angiogenesis. Nature Communications 2016, 7:10347
Chon HJ, Kim HR, Shin E, Kim C, Heo SJ, Lee C, Park JK, Noh SH, Chung HC, Rha SY.
The Clinicopathological Features and Prognostic Impact of ALK-positivity in Resected Gastric Cancer Patients. Annals of Surgical Oncology 2015, 22(12):3938-45
Lee JE*, Kim C*, Yang H, Park I, Oh N, Kim H, Hua S, Jeong H, An HJ, Kim SC, Lee GM, Koh GY, Kim H. (*Co-first author)
Novel Glycosylated VEGF Decoy Receptor, VEGF-Grab, Effectively Suppresses Tumor Angiogenesis and Progression. Molecular Cancer Therapeutics 2015, 14(2):470-9 (Selected as Highlight of issue)
Kweon GR, Seo KS, Park JH, Heo JY, Jing K, Han J, Min KN, Kim C, Koh GY, Lim K, Kang GY, Lee JU, Yim YH, Shong M, Kwak TH.
SIRT2 regulates tumour hypoxia response by promoting HIF-1α hydroxylation. Oncogene 2015, 12;34(11):1354-62
Kim C, Yang H, Fukushima Y, Saw PE, Lee J, Park JS, Park I, Jung J, Kataoka H, Lee D, Heo WD, Kim I, Jon S, Adams RH, Nishikawa SI, Uemura A, Koh GY.
Vascular RhoJ Is an Effective and Selective Target for Tumor Angiogenesis and Vascular Disruption. Cancer Cell 2014 (IF 24.755), 25(1):102-117
(highlighted by SciBx, February 13, 2014, also highlighted by Faculty of 1000 Prime)
Kim C, Chon HJ, Kang B, Kim K, Jeung HC, Chung HC, Noh SH, Rha SY.
Prediction of metachronous multiple primary cancers following the curative resection of gastric cancer. BMC Cancer 2013, 13(1):394.
Yang H*, Kim C*, Kim MJ, Scwendener AR, Alitalo K, Heston W, Kim I, Kim WJ, Koh GY. (*Co-first author)
Soluble Vascular Endothelial Growth Factor Receptor-3 Suppresses Lymphangiogenesis and Lymphatic Metastasis in Bladder Cancer. Molecular Cancer 2011, 10:36.
Lee EY, Kim C, Kim MJ, Park JY, Park SW, Song SY, Chung JB, Kim H, Bang S.
Signet Ring Cell Carcinoma of the Extrahepatic Bile Duct. Gut and Liver 2010, 4:402.
Kim JH, Rha SY, Kim C, Kim GM, Yoon SH, Kim KH, Kim MJ, Ahn JB, Chung HC, Roh JK, Kim HS.
Clinicopathologic features of metachronous or synchronous gastric cancer patients with three or more primary sites. Cancer Research and Treatment 2010, 42(4):217-224.
Moon YW, Rha SY, Jeung HC, Kim C, Hong MH, Chang H, Roh JK, Noh SH, Kim BS, Chung HC.
Outcomes of multiple salvage chemotherapy for advanced gastric cancer: implications for clinical practice and trial design. Cancer Chemother. Pharmacol. 2010, 66: 797.
Hong MH, Kim HS, Kim C, Ahn JR, Chon HJ, Shin SJ, Ahn JB, Chung HC, Rha SY.
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea. Cancer Research and Treatment 2009, 41(2):67-72.
Chon HJ, Rha SY, Im CK, Kim C, Hong MH, Kim HR, Ahn JR, Noh SH, Chung HC, Jeung HC.
Docetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trials. Cancer Research and Treatment 2009,41(4):196-204.
Kim C, Shin E, Hong S, Chon HJ, Kim HR, Ahn JR, Hong MH, Yang WI, Roh JK, Rha SY.
Clinical value of ezrin expression in primary osteosarcoma. Cancer Research and Treatment 2009, 41(3):138-144.
Kim Y, Kim JH, Kim C, Park H.
Achalasia associated with multiple esophageal diverticula. Endoscopy 2009, 41.